Lapatinib Plus Trametinib in KRAS Mutant NSCLC

Study ID
NCT02230553

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Unknown status

Trial Acronym

M14LTK

Trial Summary

This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with trametinib in patients with metastatic KRASm and PIK3CA wild-type (PIK3CAwt) non-small cell lung cancer (NSCLC). Part B is designed to perform a randomized comparison of the lapatinib-trametinib combination versus standard of care therapy in patients with metastatic KRASm/PIK3CAwt NSCLC.

More informations

Trial Starting Date

Oct 31,2014

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit